Skip to main content

Table 2 Association between low-dose aspirin usage after cancer diagnosis and cancer-specific and all-cause mortality in lung cancer patients

From: Low-dose aspirin and survival from lung cancer: a population-based cohort study

Medication usage after diagnosis Cancer-specific deaths All-cause mortality All patients Person years Cancer-specific mortality All-cause mortality
Unadjusted P Adjusteda P Unadjusted P Adjusteda P
      HR 95 % CI   HR 95 % CI   HR 95 % CI   HR 95 % CI  
Number of patients      [n = 3,635]   [n = 2,791]   [n = 3,635]   [n = 2,791]  
Aspirin non-user 1,609 1,855 2,474 4,481 1.00 Referent   1.00 Referent   1.00 Referent   1.00 Referent  
Aspirin userb 638 795 1,161 2,264 0.96 0.87, 1.05 0.36 0.96 0.85, 1.09 0.55 1.00 0.92, 1.09 0.92 0.94 0.84, 1.05 0.28
Aspirin non-user 1,609 1,855 2,474 4,481 1.00 Referent   1.00 Referent   1.00 Referent   1.00 Referent  
Aspirin user 1 to 11 prescriptionsc 440 521 670 1,189 0.94 0.85, 1.04 0.25 0.95 0.83, 1.08 0.42 0.97 0.88, 1.07 0.60 0.93 0.83, 1.05 0.24
Aspirin user ≥ 12 prescriptionsc 198 274 491 1,075 1.00 0.86, 1.17 0.96 1.01 0.84, 1.23 0.89 1.07 0.94, 1.23 0.29 0.97 0.82, 1.14 0.69
Aspirin non-user 1,609 1,855 2,474 4,481 1.00 Referent   1.00 Referent   1.00 Referent   1.00 Referent  
Aspirin user 1–365 tabletsc 353 422 541 926 0.91 0.81, 1.02 0.12 0.92 0.80, 1.06 0.27 0.96 0.86, 1.07 0.44 0.92 0.81, 1.05 0.21
Aspirin user ≥366 tabletsc 285 373 620 1,338 1.03 0.90, 1.17 0.69 1.04 0.88, 1.23 0.67 1.07 0.95, 1.20 0.28 0.97 0.84, 1.13 0.72
  1. aAdjusted for year of diagnosis, age at diagnosis, gender, radiotherapy within 6 months, chemotherapy within 6 months, surgery within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates, specifically statins and beta-blockers) and deprivation (in fifths)
  2. bMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage and a user after this time, excludes deaths in the year after cancer diagnosis
  3. cMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions from 6 months after first prescription to 6 months after 12th prescription (or 365 tablets) and a greater user after this time, excludes deaths in the year after cancer diagnosis
\